Key result
Abrupt unbridged dabigatran cessation triggers fatal mesenteric infarction in masked polycythemia vera.
Why the study?
Direct oral anticoagulant (DOAC) withdrawal carries a known risk of prothrombotic rebound, but its impact in unrecognized myeloproliferative neoplasms (MPNs) is under-reported.
Case Report (n=1)
Unbridged dabigatran withdrawal in a patient with unrecognized masked polycythaemia vera and severe hyperviscosity precipitated fatal acute mesenteric infarction, highlighting the need for mandatory myeloproliferative neoplasm screening and safety bridging in clinical trials.
Answers are grounded in this paper and cite their sources.
May warrant pre-withdrawal hematologic screening in high-risk patients; single case leaves open mandatory myeloproliferative evaluation in trials.
Background: Direct oral anticoagulant (DOAC) withdrawal carries a known risk of prothrombotic rebound, but its impact in unrecognized myeloproliferative neoplasms (MPNs) is under-reported. Objectives: To evaluate a fatal adverse drug reaction (ADR) following dabigatran withdrawal in a participant with unrecognized Masked Polycythaemia Vera (mPV) enrolled in the RE-SONATE trial (BI 1160.63), and assess associated trial safety governance failures. Case Presentation & Safety Data: A 69-year-old male with recurrent mixed arterial-venous thrombosis was enrolled in the RE-SONATE trial. Warfarin was abruptly stopped upon entry. At the end-of-treatment visit on July 27, 2009, laboratory testing revealed severe hyperviscosity: hemoglobin 19.5 g/dL, hematocrit 56.9%, platelets 493,000/μL, and PCT 0.51%. Investigators performed no therapeutic phlebotomy or anticoagulant safety bridging and discharged the participant. Eighteen days post-trial, the patient suffered fatal acute mesenteric infarction. Post-mortem molecular testing confirmed the JAK2 V617F mutation. Global WHO VigiAccess data corroborate this hazard, with ~5% of dabigatran ADRs involving haematological/hyperviscosity disorders. Discussion & Governance: Discharging a participant with extreme hyperviscosity directly violated ICH-GCP E6 and European LeukemiaNet guidelines. Furthermore, the sponsor's ongoing refusal to disclose unblinded trial records (eCRF) or insurance conditions mirrors historical criticisms of withheld trial safety data. Conclusions: Unbridged DOAC withdrawal in unrecognized mPV precipitates fatal thrombosis. Trial safety protocols must enforce mandatory MPN screening and post-trial data transparency.
No takes yet. Share an insight, caveat, or question.
Abenavoli et al. (2026) conducted a case report in Unrecognized Masked Polycythaemia Vera with recurrent mixed arterial-venous thrombosis (n=1). Abrupt dabigatran withdrawal without anticoagulant safety bridging or therapeutic phlebotomy was evaluated on Fatal acute mesenteric infarction. Unbridged dabigatran withdrawal in a 69-year-old male with unrecognized masked polycythaemia vera led to fatal acute mesenteric infarction 18 days post-trial.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: